Company news

Share this article:
Pfizer has received antitrust approval in its bid to purchase Encysive Pharmaceuticals for about $195 million. The company's offer to buy outstanding Encysive shares for $2.35 apiece expires at the end of March 31. The deal was announced last month.
Pfizer is looking to purchase Encysive to bolster is high blood pressure product portfolio.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.